Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression

Next Previous
X
Search
Trial Profile

Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lithium (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms ELIA

    • Most Recent Events

    • 17 Jul 2021 This trial has been completed in Lithuania, according to European Clinical Trials Database.
    • 30 Jan 2014 Planned End Date changed to 2 Feb 2011 as reported by German Clinical Trials Register record.
    • 13 Feb 2013 New source identified and integrated (DRKS00004551: German Clinical Trials Register).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top